Orasure Technologies INC 8-K filings

OraSure Technologies' subsidiary DNA Genotek announced FDA clearance for its Colli-PeeDx Urine Collection Kit, enabling at-home self-collection for specific STI tests on Roche diagnostic systems.

OraSure Technologies announced its first quarter 2026 financial results, with total net revenues of $27.9 million, slightly below the prior year but above the midpoint of guidance, and improved gross margins.

OraSure Technologies has entered into a cooperation agreement with Altai Capital, resulting in a new board appointment and a commitment to declassify the board.

OraSure Technologies issued a presentation to counter Altai Capital Management's claims, highlighting its strategic execution, financial performance, and strong corporate governance.

OraSure Technologies announces the resignation of Dr. David J. Shulkin from its Board of Directors, effective March 2, 2026.

OraSure Technologies reported a 29% decrease in Q4 2025 total net revenues to $26.8 million, while submitting two key product applications to the FDA for regulatory clearance.

OraSure Technologies submitted applications to the FDA for its rapid molecular self-test for CT/NG and its Colli-Pee at-home urine collection device for STIs.

OraSure Technologies' CEO and CFO have adopted Rule 10b5-1 trading plans to purchase up to $165,000 each of the company's common stock.

OraSure Technologies reports a significant 32% decline in Q3 2025 total net revenues to $27.1 million, attributing the drop to public health program funding uncertainty and customer diversification efforts.

OraSure Technologies announced a leadership transition on its Board of Directors, with Mara G. Aspinall resigning and John P. Kenny appointed as Chair, alongside the addition of Steven Boyd as a new independent director.

OraSure Technologies reported a 43% decline in Q2 2025 total net revenues to $31.2 million, primarily due to reduced COVID-19 testing demand, while launching a new proteomic research product.

OraSure Technologies' stockholders approved an amendment and restatement of the company's 2000 Stock Award Plan, increasing the authorized shares by 6,000,000, at the 2025 Annual Meeting.

OraSure Technologies finalizes its acquisition of Sherlock Biosciences, providing pro forma financial statements to illustrate the combined entity's potential performance.

Kathleen G. Weber, Chief Product Officer of OraSure Technologies, has resigned, effective June 30, 2025, and will receive severance benefits.

OraSure Technologies' Q1 2025 revenue decreased by 45% year-over-year, primarily due to a significant decline in COVID-19 related revenues, though core business revenues remained relatively stable.

OraSure Technologies' board authorizes a $40 million stock repurchase program over the next two years, funded from existing cash reserves.

OraSure Technologies finalizes the acquisition of Sherlock Biosciences, Inc., aiming to enhance its diagnostic capabilities.

OraSure Technologies announces its Q4 2024 financial results, highlighting a 10% increase in core revenue and progress in strategic transformation.

OraSure Technologies has acquired Sherlock Biosciences through a merger, aiming to expand its diagnostic capabilities with Sherlock's technology.

OraSure Technologies has acquired Sherlock Biosciences to enhance its molecular diagnostics capabilities, particularly in point-of-need testing.

OraSure Technologies reported a 55% decrease in total net revenues for Q3 2024, while making progress on strategic transformation including exiting the Risk Assessment testing business.

OraSure Technologies has increased its board size and appointed John P. Kenny as a new independent director, effective September 6, 2024.

OraSure Technologies announced its Q2 2024 financial results, highlighting revenue of $54.3 million and progress towards cash flow break-even for its core business by the end of the year.

OraSure Technologies' stockholders approved an increase in shares authorized under the stock award plan and a limitation on officer liability at the 2024 Annual Meeting.

OraSure Technologies reported a 65% decrease in total net revenue for Q1 2024, alongside announcing restructuring plans aimed at achieving cash flow breakeven by the end of the year.

OraSure Technologies reported a cybersecurity incident involving unauthorized access to company data, while also reaffirming its first-quarter revenue guidance.

OraSure Technologies announced its Q4 2023 financial results, highlighting a decrease in overall revenue due to reduced COVID-19 testing demand, but also showing progress in core business growth and strategic partnerships.